Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Promising broad-spectrum antiviral candidate against enteroviruses identified (opens in a new tab)

medicalxpress.com · 2026-09-11

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3

The source study

Preclinical evaluation of GW406108X, a broad-spectrum therapeutic blocking ULK1/2-mediated autophagy to inhibit enterovirus replication

Acta Pharmaceutica Sinica B · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 6Not checkedResearchers from NUS Medicine identified a promising antiviral compound, GW406108X, that can inhibit a range of enteroviruses, including Enterovirus D68 (EV-D68).View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 6Not checkedThe compound works by stopping viruses from exploiting a natural process in human cells that helps them multiply.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 6Not checkedIn laboratory experiments, GW406108X reduced EV-D68 levels by approximately 1,000-fold at the tested concentrations and was also active against another EV-D68 strain, Rhinovirus A16, and dengue virus serotype 2.View evidenceHide evidence

As statedapproximately 1,000-fold; activity against another EV-D68 strain, Rhinovirus A16, and dengue virus serotype 2

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 6Not checkedThe researchers found that GW406108X blocks two proteins, ULK1 and ULK2, which help start the autophagy process, reducing structures the virus uses to copy its genetic material and release new virus particles.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 6Not checkedIn preclinical studies against EV-D68 infection, no observable toxic effects were detected at the dose tested, untreated infected controls had an 83.3% mortality rate, and treated groups had 100% survival during the study period.View evidenceHide evidence

As stated83.3% mortality in untreated controls; 100% survival in treated groups; about 80% lower lung virus levels at the higher dose

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 6Not checkedThe team says the findings remain at an early, preclinical stage and further studies are needed before human clinical trials.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Preclinical evaluation of GW406108X, a broad-spectrum therapeutic blocking ULK1/2-mediated autophagy to inhibit enterovirus replication

Acta Pharmaceutica Sinica B · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed · 16 candidate papers

Selected

Preclinical evaluation of GW406108X, a broad-spectrum therapeutic blocking ULK1/2-mediated autophagy to inhibit enterovirus replication

Acta Pharmaceutica Sinica B · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.